Form 8-K - Current report:
SEC Accession No. 0001628280-22-031597
Filing Date
2022-12-08
Accepted
2022-12-08 16:46:47
Documents
15
Period of Report
2022-12-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20221202.htm   iXBRL 8-K 40660
2 EX-1.1 arrowhead-atmxsalesagreeme.htm EX-1.1 273967
3 EX-5.1 arwr_december2022atmxgdcex.htm EX-5.1 7831
7 image_0.jpg GRAPHIC 54002
  Complete submission text file 0001628280-22-031597.txt   595466

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20221202.xsd EX-101.SCH 1929
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20221202_lab.xml EX-101.LAB 24849
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20221202_pre.xml EX-101.PRE 13064
9 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20221202_htm.xml XML 11392
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 221452994
SIC: 2834 Pharmaceutical Preparations